2 weeks Ago By ABMN Staff
UBS Group cut shares of Medpace ( NASDAQ:MEDP – Free Report ) from a buy rating to a neutral rating in a report released on Friday morning, Marketbeat Ratings reports. UBS Group currently has $350.00 price target on the stock, down from their previous price target of $420.
00. Other analysts have also recently issued research reports about the stock. Robert W.
Baird cut their target price on shares of Medpace from $430.00 to $413.00 and set an outperform rating for the company in a research note on Friday, September 20th.
StockNews.com cut shares of Medpace from a buy rating to a hold rating in a research note on Friday. William Blair restated an outperform rating on shares of Medpace in a research note on Wednesday, September 11th.
Deutsche Bank Aktiengesellschaft cut their target price on shares of Medpace from $395.00 to $336.00 and set a hold rating for the company in a research note on Wednesday, July 24th.
Finally, Guggenheim cut their target price on shares of Medpace from $464.00 to $432.00 and set a buy rating for the company in a research note on Wednesday, July 24th.
Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $395.00.
Read Our Latest Research Report on Medpace Medpace Price Performance Medpace ( NASDAQ:MEDP – Get Free Report ) last announced its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating analysts’ consensus estimates of $2.
54 by $0.21. Medpace had a net margin of 16.
74% and a return on equity of 55.14%. The company had revenue of $528.
10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same quarter last year, the firm posted $1.
93 EPS. The company’s quarterly revenue was up 14.6% on a year-over-year basis.
Analysts expect that Medpace will post 11.66 earnings per share for the current year. Institutional Trading of Medpace Several hedge funds and other institutional investors have recently bought and sold shares of MEDP.
US Bancorp DE raised its stake in Medpace by 1.9% in the 4th quarter. US Bancorp DE now owns 5,269 shares of the company’s stock worth $1,615,000 after purchasing an additional 98 shares in the last quarter.
Hsbc Holdings PLC acquired a new position in shares of Medpace in the 4th quarter valued at approximately $2,394,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Medpace in the 4th quarter valued at approximately $255,000. Stifel Financial Corp raised its position in shares of Medpace by 29.
4% in the 4th quarter. Stifel Financial Corp now owns 31,379 shares of the company’s stock valued at $9,619,000 after buying an additional 7,125 shares in the last quarter. Finally, Allianz Asset Management GmbH raised its position in shares of Medpace by 10.
0% in the 4th quarter. Allianz Asset Management GmbH now owns 15,897 shares of the company’s stock valued at $4,873,000 after buying an additional 1,440 shares in the last quarter. Institutional investors and hedge funds own 77.
98% of the company’s stock. Medpace Company Profile ( Get Free Report ) Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. Featured Stories Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter .
.
